Susquehanna International Group, LLP Fsd Pharma Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$0.82 - $1.1 $17,384 - $23,320	-21,200 Reduced 39.04%	33,100 $29,000
Q4 2021 Feb 14, 2022	SELL	$0.96 - $1.63 $5,184 - $8,802	-5,400 Reduced 9.05%	54,300 $56,000
Q3 2021 Nov 15, 2021	SELL	$1.45 - $1.84 $69,165 - $87,768	-47,700 Reduced 44.41%	59,700 $94,000
Q2 2021 Aug 11, 2021	SELL	$1.56 - $2.13 $50,856 - $69,438	-32,600 Reduced 23.29%	107,400 $188,000
Q1 2021 May 17, 2021	BUY	$1.65 - $3.87 $73,920 - $173,376	44,800 Added 47.06%	140,000 $267,000
Q4 2020 Feb 16, 2021	BUY	$1.36 - $2.7 $26,656 - $52,920	19,600 Added 25.93%	95,200 $149,000
Q3 2020 Nov 16, 2020	BUY	$2.55 - $4.26 $192,780 - $322,056	75,600 New	75,600 $193,000

Ticker HUGE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 38,218,100
Market Cap $152M
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.